ACKR3 and neoplasm: CXCR7 antagonists are expected to act mainly by reducing tumor cell extravasation and thus metastasis, and blocking tumor angiogenesis, as demonstrated by CCX771, a synthetic CXCR7 ligand markedly more potent at inhibiting transendothelial migration than AMD3100.